Navigation Links
Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
Date:5/7/2009

(R) tablets; the possibility that the FDA will take enforcement action against us or one or more of our marketed drugs that do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a relatively small number of currently marketed products; our ability to obtain and maintain regulatory approvals to market and sell our products that do have FDA approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with Nasdaq listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10K, filed with the Securities and Exchange Commission (the SEC) on March 26, 2009, and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent event
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
2. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
3. Cornerstone Therapeutics Announces New Board of Directors
4. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
5. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
6. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
7. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
8. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
9. Royer Animal Health Enters Into Exclusive Agreement With MWI Veterinary Supply for U.S. Distribution of Next-Generation Therapeutics to Treat Cancer and Infections
10. Prime Therapeutics Announces Departure of President and Chief Executive Officer Timothy Dickman
11. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... The North American water storage systems market is estimated ... by 2018, at a CAGR of 21.0%, from 2013 to ... rapid pace in North America. The U.S. is experiencing high ... wastewater storage and collection, and the increased spending on modernization ... a healthy rate in Canada, and is rising at a ...
(Date:7/13/2014)... July 13, 2014 Advanced boilers ... the least amount of fossil fuels, produce high-capacity ... Due to increased global warming and climate change ... to reduce harmful gas emissions and pollutants coming ... market in the global advance boilers market., The ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study ... Scanning; 3D rendering; Layout and Animation; Image Reconstruction]: ... 2018)”, which analyzes and studies the major market ... Europe, Eastern Europe, Middle East and Africa, Asia-Pacific ... competitive landscape of the 3D imaging market, providing ...
(Date:7/13/2014)... July 13, 2014 The Pearland, Texas location ... in age from four months to 12 years of age ... classes to birthday parties and Summer Camps, is now under ... Gym of Pearland after spending over six years at ... including Gym Director. , Berry has over ten years ...
(Date:7/13/2014)... July 13, 2014 Recently, 2014QuinceaneraDresses.com, ... has unveiled its new range of gorgeous ... market, the demand for elegant Quinceanera outfits is ... beautiful items. All the company’s newly released dresses ... They are all elegant and vivid. , ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2
... sight, researchers say, , TUESDAY, Sept. 15 (HealthDay News) ... for people who suffer vision loss when the large ... extremely compelling results, because a large, longer-term clinical trial ... vein occlusion could experience a visual improvement with treatment," ...
... of virus may last up to a week , TUESDAY, ... seem to be contagious longer than patients with ordinary seasonal ... what impact the findings will have on health-care experts, recommendations ... to produce relatively mild infections in most people and recovery ...
... a nonprofit organization, and the Dartmouth Psychiatric Research ... of evidence-based practiceshave announced a partnership to develop ... and addiction treatment industries. These resources, including curricula, ... published under a new "Dartmouth PRCHazelden" imprint. ...
... activity patterns may explain why some people are able to ... according to a new study by researchers with The Miriam ... have kept the weight off for several years were shown ... areas of the brain associated with behavioral control and visual ...
... , 78 percent of Americans see pharmaceutical ... Calif., Sept. 15 The Greenlining Institute ( www.greenlining.org ... Consulting Group which shows that Americans are losing confidence in the ... The national poll found that an overwhelming number of poll respondents ...
... , , , ... Sept. 15 The upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference, to ... a backdrop for the presentation of EVEREST registry clinical results of ... the most common type of heart valve insufficiency in the United ...
Cached Medicine News:Health News:People With Swine Flu May Be Contagious Longer Than Thought 2Health News:People With Swine Flu May Be Contagious Longer Than Thought 3Health News:Hazelden and Dartmouth Psychiatric Research Center form publishing partnership 2Health News:Brain's response to seeing food may be linked to weight loss maintenance 2Health News:Survey Finds Overwhelming Majority of Americans Believe Special Interests Hindering Health Care Reform 2Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 2Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 3Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 4
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... will evaluate R7128 1000mg BID in HCV genotype 1, ... 2 or 3 ... treatment-experienced patients -, PRINCETON, N.J., May 14 ... additional cohorts of a 4-week,Phase 1 study of R7128 in ...
... (Nasdaq: KOSN ) today announced that updated data ... from a Phase,2 trial in combination with Herceptin(R) in ... Meeting of the American,Society of Clinical Oncology (ASCO), being ... 3, 2008., Abstract 1027, titled, "Phase 2 trial ...
Cached Medicine Technology:Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 2Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 3Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 4Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
Inquire...
... IGFBP-3 contains 266 amino acids and is variably ... weight estimates of between 43 and 56 kDa. ... IGF-II with high affinity but do not bind ... structurally characterized at this time, IGFBP-3 has been ...
... handle up to 180'000 tests per year ... plates and is capable of processing up ... All assay steps, from loading of the ... controlled by Windows™-based software. Between 119 (standard ...
Medicine Products: